Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.81
BIOC's Cash to Debt is ranked higher than
68% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. BIOC: 1.81 )
BIOC' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 1.81

Equity to Asset 0.34
BIOC's Equity to Asset is ranked higher than
57% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. BIOC: 0.34 )
BIOC' s 10-Year Equity to Asset Range
Min: -18.63   Max: 0.83
Current: 0.34

-18.63
0.83
Z-Score: -22.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -16055.26
BIOC's Operating margin (%) is ranked lower than
54% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. BIOC: -16055.26 )
BIOC' s 10-Year Operating margin (%) Range
Min: -1227100   Max: -5928.36
Current: -16055.26

-1227100
-5928.36
Net-margin (%) -19022.37
BIOC's Net-margin (%) is ranked lower than
54% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BIOC: -19022.37 )
BIOC' s 10-Year Net-margin (%) Range
Min: -1362900   Max: -6890.3
Current: -19022.37

-1362900
-6890.3
ROE (%) -1998.48
BIOC's ROE (%) is ranked lower than
55% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BIOC: -1998.48 )
BIOC' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -1998.48

ROA (%) -195.69
BIOC's ROA (%) is ranked lower than
53% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.94 vs. BIOC: -195.69 )
BIOC' s 10-Year ROA (%) Range
Min: -694.81   Max: -659.5
Current: -195.69

-694.81
-659.5
ROC (Joel Greenblatt) (%) -3122.31
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. BIOC: -3122.31 )
BIOC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3360.96   Max: -1614.63
Current: -3122.31

-3360.96
-1614.63
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.20
BIOC's P/B is ranked higher than
72% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. BIOC: 4.20 )
BIOC' s 10-Year P/B Range
Min: 1.88   Max: 5.65
Current: 4.2

1.88
5.65
P/S 138.83
BIOC's P/S is ranked higher than
58% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. BIOC: 138.83 )
BIOC' s 10-Year P/S Range
Min: 8.02   Max: 38.55
Current: 138.83

8.02
38.55
EV-to-EBIT -0.82
BIOC's EV-to-EBIT is ranked higher than
64% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BIOC: -0.82 )
BIOC' s 10-Year EV-to-EBIT Range
Min: -2.4   Max: -0.1
Current: -0.82

-2.4
-0.1
Current Ratio 7.83
BIOC's Current Ratio is ranked higher than
93% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. BIOC: 7.83 )
BIOC' s 10-Year Current Ratio Range
Min: 0.02   Max: 10.2
Current: 7.83

0.02
10.2
Quick Ratio 7.70
BIOC's Quick Ratio is ranked higher than
94% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. BIOC: 7.70 )
BIOC' s 10-Year Quick Ratio Range
Min: 0.02   Max: 10.09
Current: 7.7

0.02
10.09
Days Inventory 19.65
BIOC's Days Inventory is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 128.32 vs. BIOC: 19.65 )
BIOC' s 10-Year Days Inventory Range
Min: 9.26   Max: 12.06
Current: 19.65

9.26
12.06
Days Sales Outstanding 57.63
BIOC's Days Sales Outstanding is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. BIOC: 57.63 )
BIOC' s 10-Year Days Sales Outstanding Range
Min: 24.51   Max: 1825
Current: 57.63

24.51
1825

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.10
BIOC's Price/Net Cash is ranked higher than
93% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BIOC: 7.10 )
BIOC' s 10-Year Price/Net Cash Range
Min: 3.84   Max: 4.78
Current: 7.1

3.84
4.78
Price/Net Current Asset Value 6.80
BIOC's Price/Net Current Asset Value is ranked higher than
93% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. BIOC: 6.80 )
BIOC' s 10-Year Price/Net Current Asset Value Range
Min: 3.82   Max: 4.6
Current: 6.8

3.82
4.6
Price/Tangible Book 4.80
BIOC's Price/Tangible Book is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.30 vs. BIOC: 4.80 )
BIOC' s 10-Year Price/Tangible Book Range
Min: 3.25   Max: 3.88
Current: 4.8

3.25
3.88
Price/Median PS Value 1.70
BIOC's Price/Median PS Value is ranked higher than
66% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. BIOC: 1.70 )
BIOC' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.09
Current: 1.7

0.7
1.09
Earnings Yield (Greenblatt) -122.60
BIOC's Earnings Yield (Greenblatt) is ranked lower than
56% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. BIOC: -122.60 )
BIOC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -560.3   Max: 0
Current: -122.6

-560.3
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:B00.Germany,
» More Articles for BIOC

Headlines

Articles On GuruFocus.com
mbs Feb 24 2015 
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
Most active Nasdaq-traded stocks Mar 02 2015
Most active Nasdaq-traded stocks Mar 02 2015
Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor Mar 02 2015
Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor Mar 02 2015
Has Biocept Reached an Inflection Point? Feb 26 2015
Biocept, Inc. Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results Feb 25 2015
Biocept Breaks Through With Columbia Study Feb 23 2015
BUZZ-U.S. STOCKS ON THE MOVE-Biocept, Rigel, Spectrum Feb 23 2015
Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in... Feb 23 2015
BIOCEPT INC Financials Feb 14 2015
Biocept (BIOC) Stock Plummets Today After Pricing Public Offering, Warrants Feb 10 2015
BUZZ-U.S. STOCKS ON THE MOVE-RetailMeNot, Biocept, Transocean, Qualcomm Feb 10 2015
Biocept, Inc. Prices $10,000,000 Public Offering Feb 09 2015
Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer Jan 20 2015
Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer... Jan 12 2015
Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and... Jan 08 2015
Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and... Jan 08 2015
Biocept to Present at the 8th Annual OneMedForum Jan 07 2015
Biocept to Present at the 8th Annual OneMedForum Jan 07 2015
Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network Jan 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK